News Feed Opinion Blog Posts Career Updates Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
August, 2025
August 2025
M T W T F S S
 123
45678910
11121314151617
18192021222324
25262728293031
Tom Powles: Bladder sparing approaches after EVP is likely to be the SoC in MIBC
Tom Powles/X
Jan 27, 2025, 15:58

Tom Powles: Bladder sparing approaches after EVP is likely to be the SoC in MIBC

Tom Powles, Professor at the University of London, shared a post on X:

“The muscle invasive bladder cancer session AUC3 discussed perioperative durvalumab + ctDNA are changing the disease. Also, pCR of >50% is expected with EVP. Bladder sparing approaches after EVP is likely to be the standard of care if this is the case.”

tom powles

bladder cancer cancer Durvalumab OncoDaily Oncology Tom Powles
Special Coverage
Blog Posts
Aug 18, 2025, 19:17
Matteo Bauckneht: Pitfalls in PSMA-Based RLT - A Case-Based Review at EANM25
Insight
Aug 18, 2025, 18:55
NCODA Brings the BREAKWATER Trial into Practice
Blog Posts
Aug 18, 2025, 18:20
Amol Akhade: Key Late-Breaking and Practice-Changing Trials to Watch at WCLC 2025
Insight
Aug 18, 2025, 18:09
Hung Trinh Highlights Pasritamig, a First-in-Class T-Cell Engager for Prostate Cancer
Voices
Aug 18, 2025, 17:43
Building a Healthier Future for Women Also Means Building a Healthier Future for the Next Generation - Elekta Foundation
Voices
Aug 18, 2025, 17:35
Mandar Muzumdar: The Evolution of Single-Cell 3D Genomes in KRAS-Driven Cancers
Blog Posts
Aug 18, 2025, 17:21
Douglas Flora: Create the Things You Wish Existed
Blog Posts
Aug 18, 2025, 17:13
Matt Yurgelun: Thrilled to Be Joining The Jimmy Fund Radio-Telethon
Voices
Aug 18, 2025, 17:04
Striking out Cancer for Patients Like Charlie - The Jimmy Fund
Insight
Aug 18, 2025, 16:52
Darren Haywood: Pleased to Receive COSA Endorsement of the MASCC COG-IMPACT Tool
Science
Aug 18, 2025, 16:48
Petros Grivas: Highlighting Intra-Patient Tumor Heterogeneity in Prostate Cancer Research
Science
Aug 18, 2025, 16:46
How Do We Select the Best 2L Therapy for Advanced EGFR‑Mutant NSCLC After Osimertinib? - Oncogene Cancer Research